New dosing study aims to protect kids from latent TB
NCT ID NCT03730181
First seen May 08, 2026 · Last updated Jun 19, 2026 · Updated 7 times
Summary
This study looked at how to best dose two medicines, rifapentine and isoniazid, for children aged 0-12 with latent (hidden) tuberculosis infection. The goal was to find a dose that works as well as in adults to prevent the infection from turning into active TB. The study included both HIV-infected and HIV-uninfected children to ensure safety and effectiveness for all.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LATENT TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Desmond Tutu TB Center, University of Stellenbosch
Stellenbosch, South Africa
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.